Cover Image

Cancer-control outcomes of patients with metastatic hormone-sensitive prostate cancer and ≥ 10 bone metastases receiving apalutamide: a real-world cohort

Purpose: Currently available post-hoc TITAN study data indicate favorable cancer-control in metastatic hormone-sensitive prostate cancer (mHSPC) patients treated with apalutamide, even in patients with high metastatic burden, such as ≥ 10 bone metastases. However, these findings have never been vali...

Full description

Saved in:
Bibliographic Details
Main Authors: Wenzel, Mike (Author) , Filzmayer, Maximilian (Author) , Siech, Carolin (Author) , Le, Quynh Chi (Author) , Lauer, Benedikt (Author) , Theissen, Lena (Author) , Hoeh, Benedikt (Author) , Heinzer, Hans (Author) , Graefen, Markus (Author) , Steuber, Thomas (Author) , Kriegmair, Maximilian (Author) , Chun, Felix K.-H. (Author) , Mandel, Philipp (Author)
Format: Article (Journal)
Language:English
Published: December 2026
In: BMC cancer
Year: 2026, Volume: 26, Issue: 1, Pages: 1-8
ISSN:1471-2407
DOI:10.1186/s12885-026-15803-y
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s12885-026-15803-y
Get full text
Author Notes:Mike Wenzel, Maximilian Filzmayer, Carolin Siech, Quynh Chi Le, Benedikt Lauer, Lena Theissen, Benedikt Hoeh, Hans Heinzer, Markus Graefen, Thomas Steuber, Maximilian Kriegmair, Felix K.-H. Chun and Philipp Mandel
Description
Summary:Purpose: Currently available post-hoc TITAN study data indicate favorable cancer-control in metastatic hormone-sensitive prostate cancer (mHSPC) patients treated with apalutamide, even in patients with high metastatic burden, such as ≥ 10 bone metastases. However, these findings have never been validated in real-world setting. Patients and methods: We relied on the FRAMCAP (FRAnkfurt Metastatic Cancer database of the Prostate) and stratified apalutamide-treated mHSPC patients according to number of bone metastases (≥ 10 vs. < 10). Primary endpoints were time to metastatic castration-resistant prostate cancer (ttCRPC) and overall survival (OS). Finally, exploratory analyses were made against mHSPC treatment with abiraterone and docetaxel. Results: Of 105 apalutamide-treated mHSPC patients, median age was 71 years and median PSA 46 ng/ml. In total, 23% of included patients had ≥ 10 bone metastases. Patients with ≥ 10 bone metastases harbored higher PSA level at treatment start (254 vs. 29 ng/ml) and achieved less PSA response under treatment (PSA nadir 0.64 vs. 0.03 ng/ml, both p < 0.01). Regarding ttCRPC, no statistically significant difference was observed between ≥ 10 vs. < 10 bone metastases with median ttCRPC of 32 vs. 37 months (p = 0.15). Regarding OS, median OS was significantly shorter for ≥ 10 vs. < 10 bone metastases (29 vs. 64 months, hazard ratio: 2.5, p = 0.02), even after multivariable adjustment for baseline patient and tumor characteristics. In further analyses, apalutamide (32 months) showed numerically longer median ttCRPC compared to abiraterone (18 months) and docetaxel (16 months) in patients with ≥ 10 bone metastases. Conclusion: In real-world setting, apalutamide-treated mHSPC patients presenting with a high bone metastatic burden achieve virtually similar ttCRPC outcomes compared to those with a lower metastatic burden. Exploratory comparisons with other first-line doublet mHSPC treatment options indicate a potential advantage of apalutamide.
Item Description:Im Titel steht das Größer-Gleich-Zeichen
Online veröffentlicht: 2. März 2026
Gesehen am 05.05.2026
Physical Description:Online Resource
ISSN:1471-2407
DOI:10.1186/s12885-026-15803-y

Similar Items